Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS NGUYEN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1215126800
CMS profile
9342
Location
VICTORVILLE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$915.40

45 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $915.40 45

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS NGUYEN

NPI 1215126800 · CMS profile ID 9342

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

VICTORVILLE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215126800?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS NGUYEN, NPI 1215126800, CMS profile ID 9342. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215126800?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). THOMAS NGUYEN, NPI 1215126800, CMS profile ID 9342. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215126800?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
THOMAS NGUYEN, NPI 1215126800, CMS profile ID 9342, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1215126800?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

45 matching records · $915.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 45 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–45 of 45.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.5312/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959772443 CMS
Gilead Sciences, Inc. $27.0812/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929605119 CMS
Merck Sharp & Dohme LLC $12.6912/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944266417 CMS
Gilead Sciences, Inc. $21.7411/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929605117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.0511/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955754029 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.6711/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959797063 CMS
ABBVIE INC. $1.3911/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256801 CMS
ABBVIE INC. $10.4411/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256803 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.5011/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959878019 CMS
GENZYME CORPORATION $17.0210/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939153075 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.6510/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959480361 CMS
Merck Sharp & Dohme LLC $15.2210/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944228809 CMS
ABBVIE INC. $25.7210/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256799 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.2309/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955754025 CMS
ABBVIE INC. $16.0609/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256795 CMS
ABBVIE INC. $26.5209/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256797 CMS
ABBVIE INC. $27.0909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256793 CMS
ABBVIE INC. $8.7908/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256791 CMS
Janssen Biotech, Inc. $17.8908/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885603315 CMS
ABBVIE INC. $26.2608/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256789 CMS
ABBVIE INC. $26.4408/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256787 CMS
ABBVIE INC. $23.5808/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256785 CMS
ABBVIE INC. $5.1407/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256783 CMS
PFIZER INC. $19.2507/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949210137 CMS
ABBVIE INC. $26.5407/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256781 CMS
ABBVIE INC. $21.4906/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256777 CMS
ABBVIE INC. $22.2306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256779 CMS
ABBVIE INC. $21.7606/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256775 CMS
Cook Medical LLC $17.8206/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950253789 CMS
ABBVIE INC. $26.6705/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256773 CMS
ABBVIE INC. $26.8105/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256771 CMS
Merck Sharp & Dohme LLC $14.1505/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944156585 CMS
ABBVIE INC. $19.0805/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256769 CMS
ABBVIE INC. $1.0405/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256767 CMS
ABBVIE INC. $23.7305/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256763 CMS
ABBVIE INC. $9.6205/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256765 CMS
ABBVIE INC. $6.2303/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256761 CMS
Merck Sharp & Dohme LLC $22.1303/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944312199 CMS
ABBVIE INC. $24.0502/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256759 CMS
ABBVIE INC. $28.9002/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256757 CMS
Medtronic, Inc. $98.1302/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930560489 CMS
ABBVIE INC. $9.5302/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256755 CMS
ABBVIE INC. $20.0101/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256753 CMS
Merck Sharp & Dohme LLC $14.1801/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944092453 CMS
ABBVIE INC. $5.3501/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891256751 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $667.09 48
PY2020 $487.90 33
PY2021 $850.86 48
PY2022 $915.40 45
PY2023 $861.28 44
PY2024 $1,349.51 73
PY2025 $1,478.09 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,090.19 45
PY2024 Principal investigator $14,650.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/23/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692289
Principal investigator 1 Boehringer Ingelheim International GmbH $2,100.00 12/23/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692291
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/23/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692293
Principal investigator 1 Boehringer Ingelheim International GmbH $12,500.00 12/23/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692295
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 12/23/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692297
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692299
Principal investigator 1 ABBVIE INC. $5,496.40 12/04/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202528686
Principal investigator 1 ABBVIE INC. $169.40 12/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202526306
Principal investigator 1 AstraZeneca UK Limited $22,150.00 11/28/2025 Non-covered Recipient Entity
OM RESEARCH, LLC
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA No dispute reported 06/30/2026 1185538599
Principal investigator 1 ABBVIE INC. $11,174.80 10/16/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202517265
Principal investigator 1 ABBVIE INC. $2,569.00 10/09/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202515421
Principal investigator 1 ABBVIE INC. $365.40 09/18/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202511434
Principal investigator 1 Eli Lilly and Company $17,000.00 09/17/2025 Non-covered Recipient Entity
OM RESEARCH LLC
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187890160
Principal investigator 1 Boehringer Ingelheim International GmbH $12.24 08/26/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692275
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 08/26/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692277
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 08/26/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692279
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 08/26/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692281
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 08/26/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692283
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 08/26/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692285
Principal investigator 1 Boehringer Ingelheim International GmbH $133,920.00 08/19/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692287
Principal investigator 1 Boehringer Ingelheim International GmbH $328.00 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692257
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692259
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692261
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692263
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692265
Principal investigator 1 Boehringer Ingelheim International GmbH $14.90 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692267
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692269
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692271
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 08/11/2025 Non-covered Recipient Entity
Om Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220692273
Principal investigator 1 ABBVIE INC. $5,602.80 08/06/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202503405
Principal investigator 1 ABBVIE INC. $12,773.60 07/31/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202500636
Principal investigator 1 ABBVIE INC. $736.00 07/17/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202498730
Principal investigator 1 ABBVIE INC. $4,107.60 07/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202495095
Principal investigator 1 ABBVIE INC. $736.00 07/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496125
Principal investigator 1 ABBVIE INC. $6,676.60 07/02/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496127
Principal investigator 1 ABBVIE INC. $13,749.40 06/12/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202491149
Principal investigator 1 ABBVIE INC. $6,008.80 06/03/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202488121
Principal investigator 1 ABBVIE INC. $736.00 05/22/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202485789
Principal investigator 1 ABBVIE INC. $8,215.20 05/07/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202482821
Principal investigator 1 ABBVIE INC. $736.00 05/01/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202480749
Principal investigator 1 ABBVIE INC. $11,855.20 05/01/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202480751
Principal investigator 1 ABBVIE INC. $4,950.00 04/30/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202480541
Principal investigator 1 ABBVIE INC. $11,775.40 04/10/2025 Non-covered Recipient Entity
OM RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202475681
Principal investigator 1 ABBVIE INC. $522.20 03/26/2025 Non-covered Recipient Entity
OM RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202466242
Principal investigator 1 ABBVIE INC. $2,944.00 03/13/2025 Non-covered Recipient Entity
OM RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202463563